NCT06645236View on ClinicalTrials.gov

DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

NARecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2030

Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
DEVICE

therascreen® KRAS RGQ PCR Kit

The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)

Trial Locations (1)

M130BH

RECRUITING

QIAGEN Gaithersburg, Inc, Manchester

All Listed Sponsors
lead

QIAGEN Gaithersburg, Inc

INDUSTRY